Presentation is loading. Please wait.

Presentation is loading. Please wait.

ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia.

Published byStanislav Vávra Modified over 5 years ago

Similar presentations

Presentation on theme: "ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia."— Presentation transcript:

1 ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Full analysis set. *Only four episodes of severe hypoglycemia were reported in the maintenance period, which precluded statistical analysis. P values derived using a Poisson Model with logarithm of the exposure time (100 years) as offset; estimates adjusted for treatment, period, sequence, and dosing time as fixed effects and patient as random effects. BG, blood glucose. Louis Chaykin et al. Clin Diabetes 2019;37:73-81 ©2019 by American Diabetes Association

Download ppt "ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia."

Similar presentations

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.

Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.
Follow Up Questions Diabetes is caused by an increase in blood glucose. People with diabetes II also have a very high risk for developing Alzheimer’s disease.

Follow Up Questions Diabetes is caused by an increase in blood glucose. People with diabetes II also have a very high risk for developing Alzheimer’s disease.
Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients Am J Nephrol 2013;37:413-420 - DOI:10.1159/000349929 Fig. 1. Comparison.

Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients Am J Nephrol 2013;37: DOI: / Fig. 1. Comparison.
From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.
Volume 70, Issue 8, Pages (October 2006)

Volume 70, Issue 8, Pages (October 2006)
Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Modern Advances in Glucose Monitoring

Modern Advances in Glucose Monitoring
Selected efficacy and safety parameters.

Selected efficacy and safety parameters.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Similar presentations

Ads by Google